Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab plus trifluridine/tipiracil feasibility study in CLDN18.2-positive HER2-negative gastric or gastroesophageal junction adenocarcinoma
jRCTs041240161Recruiting
- Start
- Apr 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of zolbetuximab and trifluridine + tipiracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Incidence of treatment-emergent events leading to discontinuation of zolbetuximab during the study treatment period. Started Apr 2025; status: recruiting.
02
Drugs
zolbetuximabtrifluridine + tipiracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCTs041240161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041240161.